Mersana Therapeutics Inc (MRSN.OQ)
19 Jul 2018
Mersana Therapeutics said on Thursday an early stage trial testing its lead cancer drug has been put on partial hold by the U.S. Food and Drug Administration after a patient's death was possibly linked to the treatment.
July 19 Mersana Therapeutics said on Thursday its early-stage trial for its cancer drug has been put on partial hold by the U.S. health regulator after a patient's death was possibly related to the treatment.
* MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
* MERSANA APPOINTS DAVID A. SPELLMAN AS CHIEF FINANCIAL OFFICER